Increasepharm (HK) Co., Ltd was established on October 30, 2018, as a subsidiary of Beijing Increasepharm Corporation Limited, in order to actively respond to the national science and technology development plan of the Greater Bay Area and expand the group's overseas international research and development business.
Increasepharm (HK) gives an actively responds to the national plan for the development of science and technology in the Greater Bay Area. Taking advantage of Hong Kong's policy circumstance, the hub of exchanging traditional Chinese and Western medicine and culture, Increasepharm (HK) expands R&D services of aerosolized rehabilitation and nano-drug release, gradually to Southeast Asia, Europe and the United States and other countries and regions. On the one hand, the head quarters's core R&D platforms can provide related services for Hong Kong and overseas, including cooperating with Hong Kong universities and scientific research institutions or enterprises to carry out new drug R&D activities, pharmacodynamics and toxicology research, clinical research, etc. On the other hand, it can provide international drug registration, Training, testing, consulting and other comprehensive CRO service projects.
Increasepharm (HK) is carrying out multiple research projects with the Hong Kong Baptist University, the Hong Kong Polytechnic University, the Chinese University of Hong Kong and Macau University of Science and Technology. There are the screening and research and development of new drug (such as nucleic acid drug), the development of new drug delivery systems and preparations, R&D of TCM in Hong Kong, new drugs in the Mainland and international registration services.
Scan the WeChat QR code
